Global Electronic Health Record Market Set To Grow To $14.7bn By 2022

07 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Electronic Health Record Market 2017-2027: On-premise based EHR, Web-based EHR, Cloud-based EHR, Hospitals, Ambulatory Care Centres, Home Healthcare Agencies, Nursing Homes, Assisted Living Facilities, Diagnostic and Imaging Centres, Pharmacies

Electronic health records are the compilation of medical history and family medical history, which has information about a patient’s lifestyle, physical examination and laboratory results, medications prescribed, and other risk factors. Electronic health record includes the creation, development, design, and maintenance of information systems for the healthcare industry.

The electronic health record market has piqued the interest of healthcare IT companies because of its rising demand. The growth in these solutions is mainly because they offer a very cost effective, convenient, as well as better & enhanced healthcare service. The key players of the world electronic health record market are employing novel concepts and ideas, improving manufacturing techniques, and improving the current set of products, besides enhancing their profitability to gain a competitive edge over other market players.

The lead analyst of the report commented “The market for electronic health record is driven by increasing demand for quality healthcare services and solutions, increasing acceptance of mHealth and telehealth practices, demand for improved patient safety and patient care, and increasing government initiatives to promote electronic health record.

However, safeguarding the confidential information related to patients or healthcare organizations is the biggest challenge for the companies involved in this market, thus data security & privacy concerns are restraining the market growth.”

Leading companies featured in the report include McKesson Corporation, Allscripts Healthcare Solutions, Inc., athenahealth, Inc., Epic Systems Corporation, GE Healthcare, Cerner Corporation, Oracle Corporation, Philips and Infor, Inc.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read